A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials

Mashele M. Huschka, Sumithra J Mandrekar, Paul L. Schaefer, James R. Jett, Jeff A Sloan

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

BACKGROUND. In this pooled analysis, the authors examined correlations between single-item and multiple-item quality of life (QOL) measures and assessed the agreement between clinically significant changes in QOL and patient-reported adverse events (AE). METHODS. Data from 6 lung cancer clinical trials that involved 358 patients were pooled. All trials incorporated the Uniscale and 1 of 3 multiple-item assessments: the Functional Assessment for Cancer Therapy-Lung, the Lung Cancer Symptom Scale, or the Symptom Distress Scale. Spearman rank correlations and a Bland-Altman approach were used to assess agreement. Time-to-event analysis was performed using the Kaplan-Meier method. RESULTS. Correlations between the Uniscale and multiple-item assessments were substantial (correlation coefficient = 0.49-0.66). At least 1 10-point decline was reported in the Uniscale and multiple-item assessments by 58% of patients and 39% of patients, respectively. At least 1 severe AE (grade ≥3) was reported in 35% of patients postbaseline. The percent agreement between experiencing a severe AE and a decline in QOL was 48% and 59% for the Uniscale and multiple-item assessments, respectively. The median time to the first 10-point decline in QOL for the Uniscale and multiple-item assessments was 67 days and 142 days, respectively, and the median time to the first occurrence of a severe AE was 304 days. CONCLUSIONS. Information gleaned from the single-item Uniscale assessment was comparable to that gleaned from multiple-item global measures. There was moderate agreement between QOL and AE. A 10-point decline in QOL occurred earlier than Common Toxicity Criteria AE reporting. This suggests the need for inclusion of a QOL instrument in lung cancer clinical trials.

Original languageEnglish (US)
Pages (from-to)787-795
Number of pages9
JournalCancer
Volume109
Issue number4
DOIs
StatePublished - Feb 15 2007

Fingerprint

Lung Neoplasms
Quality of Life
Clinical Trials
Neoplasms
Therapeutics

Keywords

  • Adverse events
  • Lung cancer
  • Pooled analysis
  • Quality of life

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials. / Huschka, Mashele M.; Mandrekar, Sumithra J; Schaefer, Paul L.; Jett, James R.; Sloan, Jeff A.

In: Cancer, Vol. 109, No. 4, 15.02.2007, p. 787-795.

Research output: Contribution to journalArticle

@article{ed43d681e763457a85edaad532a40d37,
title = "A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials",
abstract = "BACKGROUND. In this pooled analysis, the authors examined correlations between single-item and multiple-item quality of life (QOL) measures and assessed the agreement between clinically significant changes in QOL and patient-reported adverse events (AE). METHODS. Data from 6 lung cancer clinical trials that involved 358 patients were pooled. All trials incorporated the Uniscale and 1 of 3 multiple-item assessments: the Functional Assessment for Cancer Therapy-Lung, the Lung Cancer Symptom Scale, or the Symptom Distress Scale. Spearman rank correlations and a Bland-Altman approach were used to assess agreement. Time-to-event analysis was performed using the Kaplan-Meier method. RESULTS. Correlations between the Uniscale and multiple-item assessments were substantial (correlation coefficient = 0.49-0.66). At least 1 10-point decline was reported in the Uniscale and multiple-item assessments by 58{\%} of patients and 39{\%} of patients, respectively. At least 1 severe AE (grade ≥3) was reported in 35{\%} of patients postbaseline. The percent agreement between experiencing a severe AE and a decline in QOL was 48{\%} and 59{\%} for the Uniscale and multiple-item assessments, respectively. The median time to the first 10-point decline in QOL for the Uniscale and multiple-item assessments was 67 days and 142 days, respectively, and the median time to the first occurrence of a severe AE was 304 days. CONCLUSIONS. Information gleaned from the single-item Uniscale assessment was comparable to that gleaned from multiple-item global measures. There was moderate agreement between QOL and AE. A 10-point decline in QOL occurred earlier than Common Toxicity Criteria AE reporting. This suggests the need for inclusion of a QOL instrument in lung cancer clinical trials.",
keywords = "Adverse events, Lung cancer, Pooled analysis, Quality of life",
author = "Huschka, {Mashele M.} and Mandrekar, {Sumithra J} and Schaefer, {Paul L.} and Jett, {James R.} and Sloan, {Jeff A}",
year = "2007",
month = "2",
day = "15",
doi = "10.1002/cncr.22444",
language = "English (US)",
volume = "109",
pages = "787--795",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials

AU - Huschka, Mashele M.

AU - Mandrekar, Sumithra J

AU - Schaefer, Paul L.

AU - Jett, James R.

AU - Sloan, Jeff A

PY - 2007/2/15

Y1 - 2007/2/15

N2 - BACKGROUND. In this pooled analysis, the authors examined correlations between single-item and multiple-item quality of life (QOL) measures and assessed the agreement between clinically significant changes in QOL and patient-reported adverse events (AE). METHODS. Data from 6 lung cancer clinical trials that involved 358 patients were pooled. All trials incorporated the Uniscale and 1 of 3 multiple-item assessments: the Functional Assessment for Cancer Therapy-Lung, the Lung Cancer Symptom Scale, or the Symptom Distress Scale. Spearman rank correlations and a Bland-Altman approach were used to assess agreement. Time-to-event analysis was performed using the Kaplan-Meier method. RESULTS. Correlations between the Uniscale and multiple-item assessments were substantial (correlation coefficient = 0.49-0.66). At least 1 10-point decline was reported in the Uniscale and multiple-item assessments by 58% of patients and 39% of patients, respectively. At least 1 severe AE (grade ≥3) was reported in 35% of patients postbaseline. The percent agreement between experiencing a severe AE and a decline in QOL was 48% and 59% for the Uniscale and multiple-item assessments, respectively. The median time to the first 10-point decline in QOL for the Uniscale and multiple-item assessments was 67 days and 142 days, respectively, and the median time to the first occurrence of a severe AE was 304 days. CONCLUSIONS. Information gleaned from the single-item Uniscale assessment was comparable to that gleaned from multiple-item global measures. There was moderate agreement between QOL and AE. A 10-point decline in QOL occurred earlier than Common Toxicity Criteria AE reporting. This suggests the need for inclusion of a QOL instrument in lung cancer clinical trials.

AB - BACKGROUND. In this pooled analysis, the authors examined correlations between single-item and multiple-item quality of life (QOL) measures and assessed the agreement between clinically significant changes in QOL and patient-reported adverse events (AE). METHODS. Data from 6 lung cancer clinical trials that involved 358 patients were pooled. All trials incorporated the Uniscale and 1 of 3 multiple-item assessments: the Functional Assessment for Cancer Therapy-Lung, the Lung Cancer Symptom Scale, or the Symptom Distress Scale. Spearman rank correlations and a Bland-Altman approach were used to assess agreement. Time-to-event analysis was performed using the Kaplan-Meier method. RESULTS. Correlations between the Uniscale and multiple-item assessments were substantial (correlation coefficient = 0.49-0.66). At least 1 10-point decline was reported in the Uniscale and multiple-item assessments by 58% of patients and 39% of patients, respectively. At least 1 severe AE (grade ≥3) was reported in 35% of patients postbaseline. The percent agreement between experiencing a severe AE and a decline in QOL was 48% and 59% for the Uniscale and multiple-item assessments, respectively. The median time to the first 10-point decline in QOL for the Uniscale and multiple-item assessments was 67 days and 142 days, respectively, and the median time to the first occurrence of a severe AE was 304 days. CONCLUSIONS. Information gleaned from the single-item Uniscale assessment was comparable to that gleaned from multiple-item global measures. There was moderate agreement between QOL and AE. A 10-point decline in QOL occurred earlier than Common Toxicity Criteria AE reporting. This suggests the need for inclusion of a QOL instrument in lung cancer clinical trials.

KW - Adverse events

KW - Lung cancer

KW - Pooled analysis

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=33846924355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846924355&partnerID=8YFLogxK

U2 - 10.1002/cncr.22444

DO - 10.1002/cncr.22444

M3 - Article

C2 - 17211864

AN - SCOPUS:33846924355

VL - 109

SP - 787

EP - 795

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -